Loading...
SUN-442 EGFR/ErbB2 Targeted Therapy for Aggressive Prolactinomas
Introduction: Prolactinomas are usually benign and respond well to dopamine agonist therapy. However, approximately 20% are resistant, and 10% behave aggressively and persist or recur. Treatment resistance has been associated with ErbB receptor expression, prompting us to conduct a trial of ErbB tar...
Saved in:
| Published in: | J Endocr Soc |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Endocrine Society
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6553305/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-442 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|